1921
Volume 94, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

This study aimed to survey the prevalence, patterns of antibiotic resistance, and clinical factors associated with antibiotic resistance in among the Karen and Hmong mountain people of Thailand. We recruited dyspeptic patients in the Maesod district, Tak Province, Thailand. All subjects underwent upper gastrointestinal endoscopy, and three antral gastric biopsies were obtained for rapid urease tests and culture. An epsilometer was used to determine the minimum inhibitory concentrations of amoxicillin (AMX), clarithromycin (CLR), metronidazole (MNZ), levofloxacin (LVX), ciprofloxacin (CIP), and tetracycline (TET). A total of 291 subjects were enrolled; 149 (51.2%) were infected with infection was present in 47.1% of Thai, 51.7% of Karen, and 58.7% of Hmong subjects. Antibiotic resistance was present in 75.8% including AMX (0.8%), TET (0%), CLR (5.6%), MNZ (71.8%), CIP (19.4%), LVX (19.4%), and multidrug resistance in 21.8%. Karen subjects had the highest prevalence of MNZ resistance (84.6%), and Hmong subjects had the highest prevalence of fluoroquinolone (27.3%) and multidrug (34.1%) resistance. MNZ plus fluoroquinolone (14.5%) was the most common multidrug resistance. There was no association between clinical factors and antibiotic resistance. MNZ resistance was prevalent, whereas fluoroquinolone- and multidrug-resistant infections are important problems in mountain people of Thailand.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.15-0449
2016-04-06
2017-09-25
Loading full text...

Full text loading...

/deliver/fulltext/14761645/94/4/717.html?itemId=/content/journals/10.4269/ajtmh.15-0449&mimeType=html&fmt=ahah

References

  1. Vilaichone RK, Mahachai V, Graham DY, , 2006. Helicobacter pylori diagnosis and management. Gastroenterol Clin North Am 35: 229247.[Crossref]
  2. Vilaichone RK, Panarat W, Aekpongpaisit S, Mahachai V, , 2014. Clinical characteristics and Helicobacter pylori status of gastric cancer in Thailand. Asian Pac J Cancer Prev 15: 90059008.[Crossref]
  3. Mahachai V, Vilaichone RK, , 2011. Current status of Helicobacter pylori infection in Thailand. Helicobacter Res 15: 3844.
  4. Vilaichone RK, Mahacahai VM, Tumwasorn S, Kachintorn U, , 2011. CagA genotype and metronidazole resistant strain of Helicobacter pylori in functional dyspepsia in Thailand. J Gastroenterol Hepatol 3: 4648.[Crossref]
  5. Vilaichone RK, Gumnarai P, Ratanachu-Ek T, Mahachai V, , 2013. Nationwide survey of Helicobacter pylori antibiotic resistance in Thailand. Diagn Microbiol Infect Dis 77: 346349.[Crossref]
  6. Ahmad N, Zakaria WR, Mohamed R, , 2011. Analysis of antibiotic susceptibility patterns of Helicobacter pylori isolates from Malaysia. Helicobacter 16: 4751.[Crossref]
  7. Mégraud F, Lehours P, , 2007. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 20: 280322.[Crossref]
  8. Raymond J, Lamarque D, Kalach N, Chaussade S, Burucoa C, , 2010. High level of antimicrobial resistance in French Helicobacter pylori isolates. Helicobacter 15: 2127.[Crossref]
  9. Piriyapong K, Tangaroonsanti A, Mahachai V, Vilaichone RK, , 2014. Helicobacter pylori infection impacts on functional dyspepsia in Thailand. Asian Pac J Cancer Prev 15: 1088710891.[Crossref]
  10. Vannarath S, Vilaichone RK, Rasachak B, Mairiang P, Yamaoka Y, Shiota S, Binh TT, Mahachai V, , 2014. Virulence genes of Helicobacter pylori in gastritis, peptic ulcer and gastric cancer in Laos. Asian Pac J Cancer Prev 15: 90279031.[Crossref]
  11. Prasertpetmanee S, Mahachai V, Vilaichone RK, , 2013. Improved efficacy of proton pump inhibitor–amoxicillin–clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy. Helicobacter 18: 270273.[Crossref]
  12. Boyanova L, Mitov I, , 2010. Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents. Expert Rev Anti Infect Ther 8: 5970.[Crossref]
  13. McNulty CA, Lasseter G, Shaw I, Nichols T, D'Arcy S, Lawson AJ, Glocker E, , 2012. Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? Aliment Pharmacol Ther 35: 12211230.[Crossref]
  14. Su P, Li Y, Li H, Zhang J, Lin L, Wang Q, Guo F, Ji Z, Mao J, Tang W, Shi Z, Shao W, Mao J, Zhu X, Zhang X, Tong Y, Tu H, Jiang M, Wang Z, Jin F, Yang N, Zhang J, , 2013. Antibiotic resistance of Helicobacter pylori isolated in the southeast coastal region of China. Helicobacter 18: 274279.[Crossref]
  15. Srinarong C, Siramolpiwat S, Wongcha-um A, Mahachai V, Vilaichone RK, , 2014. Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand. Asian Pac J Cancer Prev 15: 99099913.[Crossref]
  16. Mahachai V, Sirimontaporn N, Tumwasorn S, Thong-Ngam D, Vilaichone RK, , 2011. Sequential therapy in clarithromycin-sensitive and -resistant Helicobacter pylori based on polymerase chain reaction molecular test. J Gastroenterol Hepatol 26: 825828.[Crossref]
  17. Kongchayanun C, Vilaichone RK, Pornthisarn B, Amornsawadwattana S, Mahachai V, , 2012. Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand. Helicobacter 17: 282285.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.15-0449
Loading
/content/journals/10.4269/ajtmh.15-0449
Loading

Data & Media loading...

  • Received : 18 Jun 2015
  • Accepted : 09 Jan 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error